Literature DB >> 3525087

Amoxycillin-clavulanic acid combination in bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis. Preliminary report.

P E Thornley, J M Aitken, G M Nichol, N J Slevin.   

Abstract

Since 1978 we have taken an interest in lower respiratory tract infections associated with Branhamella catarrhalis in Christchurch, New Zealand. In a preliminary trial, 20 patients with bronchopulmonary infection caused by beta-lactamase-producing B. catarrhalis were treated with a combination tablet of amoxycillin 500 mg and clavulanic acid 125 mg ('Augmentin') 3 times daily for 5 days. Sputum cultures were negative for B. catarrhalis within 3 days in all patients. Two of 7 patients whose sputum cultures were positive for this organism at a review 2 to 4 weeks later were successfully treated with a further course of amoxycillin/clavulanic acid.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3525087     DOI: 10.2165/00003495-198600313-00024

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  4 in total

1.  Branhamella catarrhalis infection of the lower respiratory tract: reliable diagnosis by sputum examination.

Authors:  P E Thornley; J Aitken; C J Drennan; J MacVicar; N J Slevin
Journal:  Br Med J (Clin Res Ed)       Date:  1982-11-27

2.  Bronchopulmonary infection due to Branhamella catarrhalis: 11 cases assessed by transtracheal puncture.

Authors:  G Ninane; J Joly; M Kraytman
Journal:  Br Med J       Date:  1978-02-04

3.  Isolation of Branhamella catarrhalis from sputum and tracheal aspirate.

Authors:  J M Aitken; P E Thornley
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

4.  Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections.

Authors:  N J Slevin; J Aitken; P E Thornley
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

  4 in total
  3 in total

Review 1.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

2.  Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis.

Authors:  B A Brown; R J Wallace; C W Flanagan; R W Wilson; J I Luman; S D Redditt
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 3.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.